Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features
Authors:
Abstract
Clinical and pharmacokinetic studies were performed regarding the toxicity of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-α-D-glucopyranoside (MCNU) with other drugs, in conjunction with a peripheral blood stem cell autograft (PBSCT), for treating 26 children with acute leukemia or lymphoma associated with high-risk features. In the early phase of the study, MCNU (300 to 500 mg/m2) was administered with cytosine arabinoside (Ara-C) (1.6 to 16 g/m2),etoposide (VP-16) (0.8 to 1.6 g/m2), cyclophosphamide (CY) (100 to 200 mg/kg), or busulfan (16 mg/kg). No acute toxicity was noticed after this high-dose therapy. The dose-limiting factor of the regimens was significant but reversible interstitial pneumonitis (IP). In a subsequent trial with an MCNU/VP-16/Ara-C/CY (MCVAC) regimen in which the dose of MCNU was reduced, the risk of IP diminished. This study is still in progress, but the clinical response has so far been encouraging. Fifteen of 26 children are alive and well in unmaintained complete remission (CR) with a median follow-up period of 11 months (range, 3 to 34 months) after transplantation.Keywords
This publication has 30 references indexed in Scilit:
- Bone marrow relapse occurring as first relapse in children with acute lymphoblastic leukemiaMedical and Pediatric Oncology, 1989
- Secondary Cancers after Bone Marrow Transplantation for Leukemia or Aplastic AnemiaNew England Journal of Medicine, 1989
- PULMONARY VENOOCCLUSIVE DISEASE FOLLOWING BONE MARROW TRANSPLANTATION1Transplantation, 1989
- INTERSTITIAL PNEUMONITIS FOLLOWING AUTOLOGOUS BONE MARROW TRANSPLANTATIONTransplantation, 1988
- Allogeneic Bone Marrow Transplantation after Hyperfractionated Total-Body Irradiation and Cyclophosphamide in Children with Acute LeukemiaNew England Journal of Medicine, 1987
- Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1987
- INTERSTITIAL PNEUMONITIS FOLLOWING AUTOLOGOUS BONE MARROW TRANSPLANTATIONTransplantation, 1986
- Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow TransplantationNew England Journal of Medicine, 1986
- Pulmonary toxicity of antitumor agentsCancer Treatment Reviews, 1983
- Prediction of BCNU Pulmonary Toxicity in Patients with Malignant GliomasNew England Journal of Medicine, 1980